FLT4 and breast cancer: Lymphangiogenic receptor VEGFR3 has also been proposed to be a key molecular player in cancer cell–lymphatic crosstalk, specifically through its associated ligand VEGF-C, which is linked to poor prognosis in breast cancer [24,34].